Diagnosis is often clinical, based on the rapid onset of symptoms following exposure to triggering agents. However, definitive diagnosis can be confirmed through a muscle biopsy and caffeine-halothane contracture test (CHCT). Genetic testing for mutations in the RYR1 and CACNA1S genes can also be performed to determine susceptibility.
